A new clinical trial that launched this month is testing a new immunotherapy regimen that could offer hope to people with mesothelioma and other hard to treat cancers. It will be examining an experimental treatment that utilizes CAR-T cells, an immune cell engineered to find and attack cancer cells. The[…]
Mesothelioma
An International Study on Pediatric Patients With Rare Tumors. (PARTNER)
Primary Outcome Measures Epidemiology Use of International Recommendations Survival of children and adolescents (0-18 years) affected by Very Rare Tumors Inclusion Criteria Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. Written informed consent from the patient and/or[…]
Genetic Testing for Mesothelioma
Mesothelioma is a serious cancer that affects the lining of certain organs and body cavities. It mainly affects older adults, but it can affect people of all ages. It is rare in children, but pediatric mesothelioma is still possible. A recent study looked at pediatric peritoneal mesothelioma. The study highlights[…]
MARS 2 Trial for Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that is linked to asbestos exposure. It affects the lining of the lungs. Every year, there are over 2,500 people in the United Kingdom that are diagnosed with the cancer. A study known as MARS 2 investigated if adding surgery to chemotherapy[…]
Pleural Empyema After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is challenging to treat. For patients healthy enough, surgery is a key part of treatment, but after surgery, complications can occur. One complication that can happen is known as pleural empyema, a serious chest infection. Developing this complication can affect patient recovery.[…]
Immunotherapy Might Not Be a Good Option for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all[…]
Multimodal Therapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a deadly cancer that is mainly caused by asbestos exposure. It affects the lungs’ lining. It is a very hard to treat cancer because it is very aggressive and is often diagnosed at a late stage. New surgical and therapeutic methods are offering hope though. A[…]
Prospective Data Collection Initiative on Thoracic Malignancies (DuTOC)
Primary Outcome Measures Progression free survival Secondary outcome Measures Disease free survival Overall survival Health related quality of life Inclusion Criteria Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection; Exclusion Criteria Mentally[…]
CRS and HIPEC for Peritoneal Mesothelioma
Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In[…]
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival Secondary Outcome Measures Progression Free Survival Best Response: Objective Response Rate (ORR) Best Response: Disease Control Rate (DCR) Best Response: Clinical Benefit Rate (CBR) Other Outcome Measures Survival Rate at 12 Months Survival Rate at 18 Months Survival Rate at 24 Months Survival Rate at[…]
Skip to content